Development of a gene therapy strategy to target hepatocellular carcinoma based inhibition of protein phosphatase 2A using the α-fetoprotein promoter enhancer and pgk promoter: an in vitro and in vivo study
- Wei Li†1, 2,
- Dao-Ming Li†1,
- Kai Chen1,
- Zheng Chen2,
- Yang Zong2,
- Hong Yin1,
- Ze-Kuan Xu2,
- Yi Zhu2,
- Fei-Ran Gong3, 4, 5Email author and
- Min Tao1, 6Email author
© Li et al.; licensee BioMed Central Ltd. 2012
Received: 12 January 2012
Accepted: 7 November 2012
Published: 23 November 2012
Open Peer Review reports
Pre-publication versions of this article and author comments to reviewers are available by contacting email@example.com.
|12 Jan 2012||Submitted||Original manuscript|
|3 May 2012||Reviewed||Reviewer Report - Yasunari Nakamoto|
|12 May 2012||Reviewed||Reviewer Report - George Chen|
|26 May 2012||Reviewed||Reviewer Report - Ren-Shyan Liu|
|24 Sep 2012||Author responded||Author comments - Wei Li|
|Resubmission - Version 2|
|24 Sep 2012||Submitted||Manuscript version 2|
|17 Oct 2012||Reviewed||Reviewer Report - Yasunari Nakamoto|
|Resubmission - Version 3|
|Submitted||Manuscript version 3|
|7 Nov 2012||Editorially accepted|
|23 Nov 2012||Article published||10.1186/1471-2407-12-547|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting firstname.lastname@example.org. All previous versions of the manuscript and all author responses to the reviewers are also available.
You can find further information about the peer review system here.